低体重患者依诺肝素血栓预防剂量与抗Xa因子水平
回顾性队列研究纳入体重<55 kg住院成人,评估依诺肝素预防VTE时峰值抗Xa因子水平。35例中74%达目标范围0.2-0.5 unit/ml,中位日剂量30 mg,平均体重约44 kg,抗Xa水平与BMI或体重无显著相关性。结论提示低体重患者降低依诺肝素剂量可能合理且无安全顾虑,但需更多数据证实。
要点
- 低体重患者(<55 kg)依诺肝素预防VTE时,74%可达峰值抗Xa因子目标范围0.2-0.5 unit/ml。
- 中位日剂量30 mg,平均体重约44 kg,抗Xa水平与BMI或体重无显著相关性。
- 降低依诺肝素剂量在低体重患者中可能合理且无安全顾虑,但证据有限。
核心结论
- 低体重患者使用较低剂量依诺肝素进行VTE预防可能合理,且未见安全顾虑。
- 抗Xa因子水平与体重或BMI无显著相关性,需更多数据确认。
研究设计与样本
- 回顾性队列研究,纳入2008年1月至2017年2月在Loma Linda大学医学中心住院的体重<55 kg成人患者。
- 所有患者接受依诺肝素VTE预防并检测峰值抗Xa因子水平,共35例纳入分析。
主要发现
- 35例中74%达到峰值抗Xa因子目标范围0.2-0.5 unit/ml。
- 中位每日依诺肝素剂量为30 mg,平均体重约44 kg。
- 抗Xa因子水平与BMI或体重无显著相关性。
关键数值与推荐
- 峰值抗Xa因子目标范围为0.2-0.5 unit/ml。
- 体重<55 kg成人患者,依诺肝素用于VTE预防。
临床怎么用
- 低体重患者可考虑降低依诺肝素预防剂量,但需结合临床评估。
- 必要时监测峰值抗Xa因子水平以评估预防效果。
局限性
- 回顾性研究,样本量小(35例)。
- 需更多稳健数据确认低体重患者依诺肝素剂量调整的获益与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Enoxaparin is a widely used anticoagulant to prevent venous thromboembolism (VTE). A fixed dose is recommended for VTE prophylaxis. However, fixed prophylactic doses of enoxaparin in low-weight patients may be close to the weight-based dosing recommended for VTE treatment. OBJECTIVE: To evaluate peak anti-factor Xa (aFXa) levels in low-weight patients receiving enoxaparin for VTE prophylaxis. METHODS: Retrospective cohort of adult patients weighing < 55 kg who were hospitalized at Loma Linda University Medical Center between January 2008 and February 2017. All patients received enoxaparin for VTE prophylaxis with a peak aFXa level drawn. The primary endpoint was the proportion of patients achieving peak aFXa levels within the goal range of 0.2-0.5 unit/ml. RESULTS: Of 35 patients receiving enoxaparin for VTE prophylaxis with an appropriately timed peak aFXa level, 74% achieved goal peak aFXa levels and the median daily dose of enoxaparin was 30 mg. The mean weight was approximately 44 kg. No significant correlations between aFXa level and body mass index or body weight were found. CONCLUSION: A lower dose of enoxaparin may be reasonable in low-weight patients for VTE prophylaxis. There appears to be no safety concerns with reduced enoxaparin dosing in low-weight patients. More robust data are needed to confirm these findings.
引用
- Yam L, Bahjri K, Geslani V, et al. Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients. Pharmacotherapy. 2019. PMID: 31112313. doi:10.1002/phar.2295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。